Background: The trivalent inactivated split-influenza vaccine, Fluarix TM has been available since 1992. Aim: To assess the safety and immunogenicity of the vaccine from studies in healthy adults ...

GSK’s influenza vaccine, Fluarix Quadrivalent, has been approved by the US FDA for the immunisation of adults and children aged three years and older to help prevent disease caused by seasonal ...

The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...

Table II. Immunogenicity criteria for adults, set by the Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products. For the vaccine to be ...